Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3Dprinted at a scale and resolution that was previously unattainable.
Our innovation 3DPDMS creates microfluidics in the industry-standard material at a speed and resolution to create true biological models that propel bioinnovation across the biotech industry.
Backed by two NIH grants, Phase, Inc. is currently working with Harvard Medical School, Georgia Tech, and Virginia Tech to develop a microfluidic device that will allow researchers to develop new brain cancer treatments.
With a team of seasoned leaders in both 3D printing and biomedical engineering with advanced degrees from MIT and UC Berkeley, Phase is poised to lead the microfluidics industry in unlocking the next wave of medical breakthroughs.
11148 Treynorth Drive, Suite A
Cornelius, North Carolina 28031
